-+ 0.00%
-+ 0.00%
-+ 0.00%

HC Wainwright & Co. Initiates Coverage On Ascendis Pharma with Buy Rating, Announces Price Target of $345

Benzinga·08/27/2026 12:19:05
Listen to the news
HC Wainwright & Co. analyst Mitchell S. Kapoor initiates coverage on Ascendis Pharma (NASDAQ:ASND) with a Buy rating and announces Price Target of $345.